Emcure Pharma to acquire remaining stake in arm Zuventus Healthcare

Pune: Emcure Pharmaceuticals has announced that its
Board of Directors has approved to enter into agreement with minority shareholders of Zuventus
Healthcare Ltd., one of its subsidiaries, to acquire their shareholding.

Following the completion of this
transaction, Zuventus will become a wholly owned subsidiary of Emcure.

The transaction is expected
to close in Q2 FY 2026.

“The domestic market remains a strategic priority for Emcure. This transaction will enable full financial
consolidation of Zuventus and drive long-term value creation for Emcure, through alignment across its
domestic business and unlock synergies,” Emcure stated in a release.

In April, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited (collectively Manx).

Read also: Emcure Pharma European arm Tillomed buys strategic pharma portfolio from Manx for 19.7 million pounds

Also in April, Gennova Biopharmaceuticals Ltd., another Emcure subsidiary, announced the advancement of the development of a pathbreaking self-amplifying mRNA (saRNA) vaccine against the deadly Nipah virus. Nipah virus belongs to the Paramyxovirus family. It is one of the deadliest pathogens known to infect humans. So far, Nipah outbreaks have been confined to South and Southeast Asia, but the fruit-bat vector is found in large geographical areas across the globe covering a population of more than 2 billion people.

Read also: Emcure Pharma arm Gennova advances development of Nipah virus vaccine

Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune
engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical
products. Emcure is an R&D
driven company that develops and manufactures a wide range of differentiated pharmaceutical
products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.

Read also: Emcure Pharma Anil Kothiyal to resign as President – India Sales & Marketing

Powered by WPeMatico

Mismatch repair germline pathogenic variants could predispose to uveal melanoma

Mismatch repair (MMR) germline alterations are enriched among patients with uveal melanoma (UM), according to a study published online June 18 in JAMA Ophthalmology.

Powered by WPeMatico

Racial, ethnic differences seen in teens’ use of mental health services

There are substantial racial and ethnic differences in U.S. adolescents’ use of mental health services, according to a study published online June 18 in JAMA Network Open.

Powered by WPeMatico

Computational tool exposes hidden cancer DNA changes that may drive treatment resistance

Some of the most harmful genetic changes in cancer are also the hardest to see. These structural alterations, deep within a tumor’s DNA, can fuel aggressive growth and evade standard testing, especially when tissue samples are small or degraded.

Powered by WPeMatico

Genetics of cardiomyopathy risk in childhood cancer survivors differ by age of onset, study shows

The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from St. Jude Children’s Research Hospital have helped address this gap, assessing whether variant trends seen in the general population also apply to late-onset cardiomyopathy in five-year survivors of childhood cancer.

Powered by WPeMatico

Up to 40 years to get diagnosed with lupus: Research highlights devastating impact of delays on patients

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that can last decades—in diagnosing lupus, an auto-immune condition.

Powered by WPeMatico

GSK application for expanded use of RSV vaccine in adults aged 18-49 accepted in Japan

GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18-49 at increased risk of severe RSV disease.

Arexvy was the first vaccine approved in Japan for adults aged 60 years and older for the prevention of RSV disease, and for those aged 50 years and older at increased risk for severe RSV disease.

RSV is a common, contagious virus affecting the lungs and breathing passages impacting an estimated 64 million people of all ages globally every year. RSV can exacerbate certain medical conditions, and lead to severe illness resulting in hospitalisation and even death.

This regulatory submission is supported by positive results from phase IIIb trial NCT063894875 which showed a non-inferior immune response in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions, to that observed in adults aged 60 and above. The safety and reactogenicity data were consistent with results from the phase III programme that supported the initial approval of the vaccine in Japan.

Regulatory submissions to expand the indications for the RSV vaccine continue in other geographies including the US and Europe.

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E adjuvant.

The MHLW has approved GSK’s RSV vaccine for the prevention of RSV (respiratory syncytial virus) disease for adults aged 60 years and above and adults aged 50 and older who are considered at increased risk of severe RSV disease. The use of this vaccine should be in accordance with official recommendations. As with any vaccine, a protective immune response may not be elicited in all vaccinees.

The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus.

Powered by WPeMatico

Patient contracts Hepatitis B after Blood Transfusion: Hospital slapped Rs 6.35 Lakh Compensation for Medical Negligence

Coimbatore: The District Consumer Disputes Redressal Commission (DCDRC) in Coimbatore recently directed a private hospital to pay Rs 6.35 lakh to a patient who contracted Hepatitis B after undergoing a blood transfusion at the hospital while being admitted there for delivery.

While considering the consumer complaint filed by the woman, the District Consumer Court directed the hospital to pay Rs 5 lakh as compensation and Rs 1.35 lakh towards medical expenses for the patient, who developed liver-related complications after contracting Hepatitis B. Apart from this, the hospital has also been directed to pay Rs 5000 as litigation expenses.

During her pregnancy, the patient, who hails from Coimbatore, visited the hospital on Puliakulam Road for regular check-ups to ensure that her baby was healthy. When she visited the facility on October 3, 2022, she was advised to undergo a blood test; the report showed that the presence of HBsAg (Hepatitis B surface antigen) in her blood was non-reactive.

Consequently, on May 2, 2023, the child was born, and during the postnatal period, the patient experienced a blood loss of 1,000 ml. Therefore, the attending doctor arranged for a transfusion of one unit of packed red cells from the hospital’s blood bank. Later, she was discharged on the same day.

Also Read: SC raises concerns over High-risk Label for Transgender blood donors

As per the latest media report by the Times of India, after getting discharged from the hospital, the patient started experiencing joint pain and consulted another hospital for treatment. The treating doctor at the second hospital advised a blood test, which the patient underwent on August 1, 2023. However, she was shocked to find that the blood test report showed that she was HBsAg positive. This confirmed that the patient had contracted Hepatitis B.

The patient claimed that between April 30 and August 1, 2023, she was not admitted to any other hospital apart from the one on Puliakulam Road. She did not even take any medication from any other hospital. Further, she submitted that before being diagnosed with Hepatitis B, she never suffered from jaundice or any liver-related disease.

TOI has reported that due to the illness, the patient’s liver was affected, and this caused trauma to her entire family. Following this, the patient filed a complaint with the Coimbatore District Consumer Court. The Commission president, R Thangavel and members P Marimuthu and G Suguna directed the hospital to compensate the patient by paying Rs 1.35 lakh as medical expenses and Rs 5 lakh as compensation for the mental agony and emotional trauma caused by the hospital’s negligence and deficiency in service.

Also Read: Pregnant Woman Dies After suspected Blood Transfusion mix-up at SMS Hospital

Powered by WPeMatico

Mizoram Health Minister calls for urgent action as State leads in HIV cases

Aizawl: Mizoram Health Minister Lalrinpuii has called for urgent and coordinated efforts to address the state’s HIV crisis, as Mizoram continues to record the highest HIV prevalence rate in India at 2.73%. 

Speaking at the governing body meeting of the Mizoram State AIDS Control Society (MSACS) in Aizawl on Wednesday, Lalrinpuii, who also chairs the society, said the situation leaves no room for complacency and requires intensified intervention across sectors, news agency UNI reported.

MSACS Project Director Dr Jane Rinzuali Ralte informed the meeting that 2,069 new cases of People Living with HIV (PLHIV) were registered at the state’s 14 Antiretroviral Therapy (ART) centres during 2024–2025. Of those receiving treatment, 97.7% have achieved viral suppression, meaning they can no longer transmit the virus to others, she said.

Also Read:8 Mizoram Govt Health facilities receive NQAS Certification

While Mizoram remains at the top in terms of HIV prevalence, Ralte noted a steady decline in new cases over the past five years, describing it as a positive trend, though far from satisfactory.

According to a UNI report, as part of its multi-pronged response, MSACS conducted HIV testing and treatment literacy campaigns in de-addiction centres, along with intensive Information, Education and Communication (IEC) outreach across all 11 districts last year. Candlelight vigils were also held in memory of those who lost their lives to HIV/AIDS.

Ralte added that the Mizoram State Blood Transfusion Council (MSBTC) had won the prestigious ‘Excellence in Blood Donation 2023–24’ award, being recognised as the best-performing council in the entire Northeast.

Medical Dialogues had earlier reported that eight government health facilities in Mizoram have been newly ranked among the best-performing public hospitals in India under the National Quality Assurance Standards (NQAS).

According to Dr Lily Chhakchhuak, Mission Director of the National Health Mission under the Health & Family Welfare Department, the newly accredited facilities include Kawnpui PHC (91.42%), Pangzawl PHC (96.26%), Chhingchhip PHC (93.80%), Hrangchalkawn UPHC (93.35%), Lungsen PHC (88.22%), Cherhlun PHC (89.66%), Sangau PHC (89.03%), and Chhuarlung PHC (95.30%).       

Also Read:HMPV Virus Cases: Mizoram forms Committee to address rising concerns

Powered by WPeMatico

Medical Admission Scam: Mumbai Woman Duped of Rs 45 Lakh, 1 Arrested, 3 Absconding

Mumbai- A case of medical admission fraud has come to light from Mumbai, where a woman was duped of Rs 45 lakh by promising to get a medical college seat for her daughter. However, Versova police have arrested one accused, and three others are still absconding.

The victim was identified resident of Andheri. She was looking for a medical seat for her younger daughter, who had scored 315 marks in the National Eligibility and Entrance Test (NEET).

Also Read: ED Crackdown on 4 WB Medical Colleges, Attaches Rs 12.33 Crore in NRI Admission Fraud

Meanwhile, the accused have been identified as Meghna Santosh Satpute, Nitesh Pawar, Rakesh Gawade and a man called ‘Sawant Kaka’. Satpute was an acquaintance of of the victim.

According to a FreePressJournal Media news report, when she was looking for a medical seat for her daughter, her acquaintance Satpute contacted her. She claimed that she could get admission under the management quota in a medical college in Sindhudurg, Maharashtra.

The accused then introduced the victim to three other accused, who allegedly claimed to be trustees of the college and even claimed to be relatives of a senior BJP leader to win her confidence. After meeting them, the accused asked her to transfer Rs 45 lakh via NEFT and cash over a period of time. However, believing their claims, she transferred the money 

Even after this, there was no talk about admission and when the mother started asking questions about the promised admission, the accused started threatening her and eventually broke all contact with the victim.

After this, she complained and an investigation revealed that the accused had no connection with the said medical college. After the complaint, Satpute was arrested, however, the police are now searching for three other accused. At present, the case has been registered, and further investigation is going on.

Medical Dialogues  earlier reported a similar case where 5 individuals have been booked for duping around Rs 15 lakh from a man on the pretext of securing admission in MBBS in ESIC Medical College, Faridabad.
Also Read: Man Duped of Rs 15 Lakh in ESIC Medical College Faridabad MBBS Seat Promise, 5 Booked

Powered by WPeMatico